A biotechnology firm is currently developing a new vaccine using mRNA technology. This product will take 3 years to develop and will cost $600 million per year during the development stage. During the fourth year, the new product is expected to generate revenues of $250 million with an expected growth rate of 15% per year until the end of the tenth year. After the first 10-year period, revenues are expected to grow at the rate of only 4% and continue at that rate forever. However, after 10 years of operation, the firm will incur new R&D expenditures of $45 million per year forever in order to adjust the vaccine against the emergence of virus variants. The cost of capital is estimated to be 10%. The net present value (NPV) of the project is: